louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06974864: Burnout vs Resilience Among Healthcare Workers After the Recent Aggression in Lebanon
Official title: Burnout vs Resilience: A Cross-sectional Study Among Healthcare Workers After the Recent Aggression in Lebanon
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Burnout
Resilience
Lead sponsor: Hopital Libanais Geitaoui
Sponsor class: OTHER
First posted: 2025-05-16
Enrollment: 382
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthcare workers

Brief summary: The purpose of this study is to assess the extent of burnout and the prevalence of resilience traits among healthcare workers in Lebanon, specifically after the recent Israeli aggression. This study will also explore factors related to burnout and resilience, as well as the relationship between resilience and mental well-being.


Eligibility criteria: Inclusion Criteria:

* Healthcare workers currently working in Lebanon including physicians, nurses, and other allied health workers (physiotherapists, psychologists, radiology technicians, occupational therapist, midwives, paramedics...).
* Students/interns training in these professions are also included.

Exclusion Criteria:

* non-healthcare staff
* healthcare workers who stopped working during war

Primary outcomes:
measure: Oldenburg Burnout Inventory (OLBI) scale
timeFrame: February 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Lebanese Hospital Geitaoui
Study officials:
References:
Clinical trial NCT03661164: Iontophoretic Transepithelial Corneal Cross-linking in Pediatric Patients
Official title: Factors Influencing Keratoconus Progression After Iontophoretic Transepithelial Corneal Cross-linking in Pediatric Patients: Three Year Follow up
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Keratoconus
Lead sponsor: Bambino Gesù Hospital and Research Institute
Sponsor class: OTHER
First posted: 2018-09-07
Enrollment: 22
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Thirtyfive eyes of 22 consecutive pediatric patients (5 female and 17 male; mean age 14.3±2.5 \[SD\] years; range, 9 to 18 years) affected by keratoconus (diagnosis established accord-ing to global consensus on keratoconus and ectatic diseases) who underwent transepithelial corneal cross-linking by iontophoresis are enrolled in this retrospective study.

Brief summary: To report three year follow up in pediatric patients with keratoconus after iontophoretic transepithelial corneal cross-linking (CXL) to assess preoperative factors that may influence ectasia progression

Detailed description: Purpose: To report three year follow up in pediatric patients with keratoconus after iontophoretic transepithelial corneal cross-linking (CXL) to assess preoperative factors that may influence ectasia progression.

Methods: Thirthyfive eyes of 22 consecutive pediatric patients (mean age 14.3±2.5 years) with keratoconus are evaluated in this retrospective study. Subgroup A and B are made up in function of progression in maximum K (Kmax,) defined as steepening of 1.0 diopter or more recorded three year after CXL. Corrected distance visual acuity (CDVA), spherical equivalent, topographic cone location, Kmax, posterior elevation of the thinnest point and thinnest point are evaluated. A paired Student t test is used to compare preoperative and 12, 24, and 36 month postoperative da-ta. A P value \<0.05 was considered significant.

Eligibility criteria: Inclusion Criteria:

clinical diagnosis of Keratoconus age \< 18 years at the treatment iontophoretic corneal cross linking performed at least 3 years before

Exclusion Criteria:

age \> 18 years at the treatment

I

Primary outcomes:
measure: : Preoperative Kmax
timeFrame: 3 years
measure: posterior elevation of the thinnest point
timeFrame: 3 years
measure: cone location
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01773564: Comparison of Two New Generation Dressings in Intensive Care (ADVANCED)
Official title: Comparison Between Two Types of Semipermeable Dressings of New Generation in the Prevention of Intravascular Catheters Related Complications in Intensive Care.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Complication of Catheter
Keywords: Dressings, Prevention,
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2013-01-23
Enrollment: 628
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Intravascular devices in intensive care units are often associated to complications. The investigators estimate that 23.5% of catheters placed and used in intensive care are subject to at least one complication; the investigators goal is to demonstrate the effectiveness of the new Tegaderm ™ IV Advanced dressings to achieve a decrease of 35% in the number of complications associated with intravascular catheters in intensive care.

Detailed description: randomized controlled trial of 2 intravascular dressings in Intensive care unit

Eligibility criteria: Inclusion Criteria:

* Patients over 18 years with a central venous catheter, an arterial catheter, a hemodialysis catheter, a Swan Ganz catheter or a peripheral catheter inserted in the ICU or within the 24 before their arrival at the ICU in another ICU setting.
* Patients benefiting from the social security protection.

Exclusion Criteria:

* Patients under 18 years of age,
* Patients having known allergy or sensitivity to adhesive dressing materials

Primary outcomes:
measure: Number of catheters presenting any kind of complications..
timeFrame: From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.
Secondary outcomes:
measure: Number of catheter infections related to poor adherent dressings.
timeFrame: From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks
Other outcomes:
measure: Number of participants presenting allergic adverse events
timeFrame: From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.
measure: Costs of each dressing type strategy.
timeFrame: From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.
Locations:
city: Grenoble
country: France
facility: University Hospital of Grenoble
Study officials:
References:
Clinical trial NCT02474264: The Link Between BRCA Mutation and Endothelial Function
Official title: The Link Between BRCA Mutation and Endothelial Function - A Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: BRCA1 Gene Mutation
BRCA2 Gene Mutation
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2015-06-17
Enrollment: 82
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: This study evaluates the effect of BRCA1\&2 mutations on cardiovascular diseases by to comparing the endothelial function of male BRCA mutation carriers with that of age matched non-BRCA mutation carriers.


Eligibility criteria: Inclusion Criteria:

* Known carrier or non-carrier, confirmed by genetic testing of BRCA 1/2 mutation
* Able and willing to sign an informed consent

Exclusion Criteria:

* History of, or current, malignancy
* History of:

  * Myocardial infarction
  * Ischemic or Hemorrhagic cerebrovascular conditions
  * Arterial embolic and thrombotic events
  * Ischemic heart disease
  * Prior coronary artery or ilio-femoral artery revascularization (percutaneous or surgical procedures)
  * Peripheral vascular disease (e.g. claudication, prior vascular surgery/intervention)

Primary outcomes:
measure: reactive hyperemia index will be assessed using the Endo-PAT2000
timeFrame: at baseline
Secondary outcomes:
measure: The level of high sensitivity troponin (hsTn) - a cardiovascular risk biomarker will be measured
timeFrame: at baseline
measure: The level of C-reactive protein - a cardiovascular risk biomarker will be measured
timeFrame: at baseline
measure: The level of D-dimer - a cardiovascular risk biomarker will be measured
timeFrame: at baseline
measure: The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) - a cardiovascular risk biomarker will be measured
timeFrame: at baseline
measure: Endothelial Progenitor Cells profile (EPC) - will be characterized to evaluate endothelial injury.
timeFrame: at baseline
measure: Circulating Endothelial Cells profile (CEC) - will be characterized to evaluate endothelial injury.
timeFrame: at baseline
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Rabin Medical Center, Beilinson Hospital
Study officials:
affiliation: Rabn Medical Center, Beilinson Campus
name: David Margel, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04758364: Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy
Official title: Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gait Disorder, Sensorimotor
Diabetes Mellitus, Type 2
Keywords: Mini-Mental State Examination
gait
aerobic capacity
HbA1c
muscle
hypertension
glucose
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2021-02-17
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Type 2 Diabetic individuals without neuropathy

Brief summary: This study planned to investigate the role of potential explanatory factors effecting the speed of gait such as muscle mass, aerobic capacity, physical activity status, cognitive function, blood pressure, and metabolic measures considering age, sex, and education years in diabetic individuals without neuropathy.

Detailed description: Type 2 diabetic people will be screened by clinical symptoms of neuropathy and DN4 questionnaire. Among those who did not have neuropathic symptoms or who have DN4 score below 4 will be considered for the study.Then aerobic capacity will be measured by a cycle ergometer and VO2max will be obtained. Weight, body mass index and muscle mass will be measured by bioimpedance analysis. Physical activity status will be determined by International Physical Activity Score (IPAQ). Cognitive function will be evaluated by Mini Mental test. HbA1c and fasting blood glucose will be measured in venous blood after overnight fasting. Blood pressure will be measured in the sitting position after resting from the left arm. Speed of gait will be measured by an accelerometer.Then, the effect of above mentioned factors on speed of gait will be studied.

Eligibility criteria: Inclusion Criteria:

* Individuals with Diabetes Mellitus less than 10 years but longer than 1 year
* Absence of neuropathic symptoms
* DN4 questionnaire sore less than 4

Exclusion Criteria:

Individuals who had

* insulin therapy,
* poor glycemic control,
* manifesting cardiovascular disease,
* retinopathy or other visual problems,
* diabetic neuropathy,
* nephropathy,
* cerebrovascular disease,
* cognitive impairment,
* heart failure,
* alcohol or cigarette dependence,
* cancer,
* chemo/radiotherapy,
* foot ulcer,
* orthopedical or surgical problems
* wheel-chair or any assistive devices for ambulation
* prominent knee or hip arthritis, prosthesis

Primary outcomes:
measure: gait speed
timeFrame: The gait speed will be measured once within a month after the participants enrolled.
Secondary outcomes:
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
Study officials:
References:
Clinical trial NCT04751864: Brain Stimulation & Generalized Anxiety Study
Official title: Fisher Wallace Brain Stimulation & Generalized Anxiety Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE4
Conditions: Anxiety
Generalized Anxiety Disorder
Generalized Anxiety
Lead sponsor: ProofPilot
Sponsor class: INDUSTRY
Collaborators: name: Fisher Wallace
First posted: 2021-02-12
Enrollment: 150
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Participants randomized into Sham and Active device arms for four weeks. At the week 5 crossover, participants in sham arm receive active device.
Primary purpose: TREATMENT

Brief summary: Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.


Eligibility criteria: Inclusion Criteria:

* Age greater than 21
* US resident
* Can receive packages to their home via UPS/Fedex/USPS
* Licensed Physician Diagnosis of Generalized Anxiety Disorder
* Beck Anxiety Inventory Score between 8 and 25
* Read/write English
* Have not contemplated suicide in the past year
* Not been institutionalized for mental health issues.
* Not currently experiencing problems with alcohol or drug abuse
* Can commit to not drinking alcohol 4 hours before bedtime for the duration of the study
* Can commit to two (2) 20 minute sessions per day for 8 weeks
* Not under medical supervision for serious medical condition
* Not currently being treated for or suspect a mental health issue
* Has not used a brain stimulation treatment in one year
* No suspected or known history of heart disease
* No pacemaker, or any form of medical electronics, including but not limited to a deep - brain stimulator, electronic stent, etc.
* Not taking opioids
* Are a resident of states in which we have licensed medical professionals
* Does not have any co-occurring significant psychiatric disorder that would impair - participant's particationion.
* Does not use any illicit drugs
* Not participating in any other anxiety study
* Not taking medications affecting the nervous system (e.g. psychiatric medications)
* Not taking hypnotics or any sleep aid or marijuana (in any form)

Primary outcomes:
measure: Change in Beck Anxiety Inventory (BAI) Score
timeFrame: baseline versus week 4
Secondary outcomes:
measure: Change in Promise Sleep-SD
timeFrame: baseline versus week 4
measure: Change in Patient Health Questionnaire - 8 (PHQ-8)
timeFrame: baseline versus week 4
measure: Change in Beck Anxiety Inventory (BAI) Score
timeFrame: week 4 versus week 8
measure: Device safety, tolerability and adherence as measured by SAFTEE
timeFrame: baseline versus week 8
Other outcomes:
Locations:
city: New York
country: United States
facility: ProofPilot (Remote Virtual Trial)
state: New York
Study officials:
References:
Clinical trial NCT04399564: Temporary vs.Long Term Hemodialysis Catheter on Central Vein Stenosis
Official title: Effect of Temporary vs.Long Term Hemodialysis Catheter on Central Vein Stenosis in Long-term Hemodialysis Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stenosis of Arteriovenous Dialysis Fistula
Keywords: central vein stenosis
temporary hemodialysis catheters
long term hemodialysis catheter
Lead sponsor: Shanghai Pudong Hospital
Sponsor class: OTHER
First posted: 2020-05-22
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trial
Primary purpose: PREVENTION

Brief summary: Vascular access (VA) is the most important for carrying out hemodialysis, yet it may bring in complications and leads to hemodialysis quality decline. This study aimed to explore the impact of vascular access types, including temporary vs.long term hemodialysis catheter on central vein stenosis.

Detailed description: It is unknown whether central vein stenosis occurs after temporary or long term hemodialysis catheter in long-term hemodialysis patients. this study will aim to explore this question. Study design is randomized, controlled trial. One arm is temporary catheters in the internal jugular vein, and another arm is tunneled cuffed hemodialysis cather. 2\*2 is randomly distributed.

The main outcome: central vein stenosis diagnosed by venography. The secondary outcome: the time of infection, and catheter patency. Study period: one year

Eligibility criteria: Inclusion Criteria:

* need to receive long-term hemodialysis no arteriovenous shunts or immature arteriovenous shunts

Exclusion Criteria:

* Uremia with heart failure or lung function failure

Primary outcomes:
measure: central vein stenosis
timeFrame: 8 weeks after temporary or long-term hemodialysis catheter
Secondary outcomes:
measure: time of infection
timeFrame: 8 weeks
measure: catheter unobstructed degree
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Shanghai Pudong Hospital
name: Hui Min Jin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01646164: Effect of Dill Seed on Uterus Contractions Pattern
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uterus Contractions Pattern
Keywords: Dill seed
Pattern of uterus contractions
Active phase of labor
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2012-07-20
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pregnance women

Brief summary: Dill is herbaceous and aromatic herb used in order to convenient and shorter labor in Iran. The objective of this study was to evaluate the effect of Dill seed on uterus contractions in active phase of labor.


Eligibility criteria: Inclusion Criteria:

* 18-35 yrs, primiparous, having single fetus with cephalic presentation, gestational age 37-42 weeks, having no medical diseases, having no history of hospitalization due to psychological diseases, having no addiction to cigarette, having no complications during pregnancy such as hypertension, and BMI\< 26.

Primary outcomes:
measure: Dill seed
timeFrame: up to 15 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04664764: Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
Official title: The Effect of Long- and Intermediate-acting Insulins on Glycemic Control and Risk of Hypoglycemia Among Toddlers and Preschool Children With Newly Onset Type 1 Diabetes Mellitus: A Randomized Three Armed Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
type1diabetes
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2020-12-11
Enrollment: 60
Sex: ALL
Minimum age (years): 2
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Achieving glycemic control without risking hypoglycemia imposes a major challenge in the management of toddlers and preschool children with Type 1 diabetes(T1D). Optimal insulin therapy for young children with T1D should provide effective glycemic control while minimizing the risk of hypoglycemia and hyperglycemia. Despite the advantages of the basal-bolus insulin regimens, hypoglycemia still presents a major barrier in achieving desirable glycemic control. Objectives: To compare the effectiveness of insulin degludec to insulin glargine and NPH in toddlers and preschool children with T1D in terms of glycosylated hemoglobin(HbA1C) and frequency of hypoglycemic episodes.


Eligibility criteria: Inclusion Criteria:

* Toddlers and preschool children with T1D on insulin therapy

Exclusion Criteria:

* patients with other medical conditions (i.e. celiac disease or autoimmune thyroiditis), patients with other types of diabetes mellitus (i.e. maturity onset diabetes of youth (MODY) and type 2 diabetes mellitus), patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes, renal impairment due to cause other than diabetes, hypertension, patients taking any vitamins or food supplements one month before study and participation in a previous investigational drug study within 3 months preceding screening.

Primary outcomes:
measure: to compare the effectiveness of insulin degludec to insulin glargine and NPH
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
affiliation: Ain Shams University
name: Safinaz El Habashy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02411864: Optimal Low B-value in Intravoxel Incoherent Motion Diffusion-weighted MR Imaging of the Brain
Official title: Can the Distribution of Low B-value and the NEX Influence the Pseudodiffusion Parameter Derived From IVIM in Brain?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Volunteers
Keywords: IVIM
brain
diffusion-weighted imaging
Lead sponsor: Tang-Du Hospital
Sponsor class: OTHER
First posted: 2015-04-08
Enrollment: 20
Sex: MALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: healthy volunteers

Brief summary: Our research aims to reveal whether the low b-values distribution and the number of NEX for each b value will influence the accuracy of pseudodiffusion parameter derived from IVIM in brain.

Detailed description: As an improved MRI technique, diffusion-weighted imaging (DWI) is considered the most sensitive for early pathological changes. Perfusion measurement has been shown to improve sensitivity and predictive value for tumor grading and prognosis, also as a predicator of recovery with reperfusion in patients of acute ischemic stroke.Our research aims to reveal whether the low b-values distribution and the number of NEX for each b value will influence the accuracy of pseudodiffusion parameter derived from IVIM in brain.

Eligibility criteria: Inclusion Criteria:

* no hypertension or cerebral vascular diseases,
* no systemic metabolic disease;
* no infection or fever;
* no use of corticosteroid drugs;
* no MRI contraindication.

Exclusion Criteria:

Primary outcomes:
measure: Parameters D* and f in healthy white matter or gray mater
timeFrame: 2-3 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: